期刊文献+

UPLC法测定患者美罗培南的血药浓度 被引量:7

Determination of Meropenem Plasma Concentration in Patients by UPLC
下载PDF
导出
摘要 目的建立超高效液相色谱法测定人血浆中美罗培南的方法,并用该法对临床使用美罗培南的患者进行血药浓度测定。方法色谱柱为Zorbax Eclipse Plus C_(18)柱(2.1mm×100mm,1.8μm),流动相为乙腈-0.01mol·L^(-1)磷酸二氢钾缓冲液(6.3∶93.7,V/V),流速:0.4ml·min^(-1),柱温:30℃,检测波长:299nm,内标为甲硝唑。结果美罗培南与血浆中其它组分分离良好,线性范围为0.5~80.0μg·ml^(-1),日内和日间RSD均小于10%,美罗培南平均提取回收率为82.2%,方法平均回收率为101.9%。测定10例患者美罗培南谷浓度范围为0.73~32.30μg·ml^(-1),浓度值差异较大,其中3例患者的血药谷浓度低于4.0μg·ml^(-1)。结论该方法快速、灵敏、准确,适用于美罗培南临床血药浓度监测。临床患者美罗培南的谷浓度差异较大,测定患者美罗培南的血药浓度对促进美罗培南在临床合理应用具有重要意义。 Objective To establish a UPLC method for determining the meropenem concentration in human plasma and to apply this method to patients.Methods The samples were analyzed by an Agilent 1290 UPLC system with a Zorbax Eclipse Plus C(18) column(2.1 mm×100 mm,1.8μm)at 30℃at a flow rate of 0.4 ml·min^-1,and UV detection wavelength of 299 nm.The mobile phase was acetonitrile-0.01 mol·L^-1 KH2PO4(40∶60,V/V).Results The calibration curve was linear within the range of 0.5-80.0μg·ml^-1 using a 0.2 ml sample volume.The intra-and inter-day precisions were both below 10%.The extraction and recovery rates were 82.2% and 101.9%,respectively.The individual variability of meropenem trough concentrations was high among the 10 patients,ranging from 0.73μg·ml^-1 to 32.30μg·ml^-1,while the concentrations in 3 patients were much lower than 4.0μg·ml^-1.Conclusion This UPLC method is sensitive,quick and accurate,which can be used for therapeutic drug monitoring(TDM)of meropenem.Determination of meropenem concentrations in patients′plasma is necessary.
机构地区 解放军
出处 《解放军药学学报》 CAS CSCD 2018年第1期37-39,42,共4页 Pharmaceutical Journal of Chinese People's Liberation Army
关键词 美罗培南 UPLC 血药浓度 meropenem UPLC drug concentration in plasma
  • 相关文献

参考文献7

二级参考文献134

  • 1赵彩芸,李家泰,张莉,张朴,刘燕.单次静脉美罗培南在健康人体的药代动力学[J].中国临床药理学杂志,2004,20(3):189-192. 被引量:25
  • 2倪桂芬.HPLC法测定人血清中美罗培南浓度[J].中国药师,2005,8(7):577-578. 被引量:7
  • 3Raveh D, Yinnon AM, Broide E, et al. Susceptibilities of ESBL-producing enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid [J]. Chemotherapy, 2007, 53 (3) : 185-189.
  • 4Yang K, Guglielmo BJ. Diagnosis and treatment of extended- spectrum and AmpC beta-lactamase-producing organisms [J]. AnnPharmaeother, 2007, 41 (9) : 1427-1435.
  • 5Zhou QT, He B, Zhang C, et al. Pharmacokineties and phar-macodynamics of meropenem in elderly chinese with lower res- piratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmaco- dynamics study[J].DrugsAging, 2011, 28 (11) : 903-912.
  • 6Li C, Kuti JL, Nightingale CH, et al. Population pharmaco- kinetic analysis and dosing regimen optimization of meropenem in adult patients [J]. J Clin Pharmacol, 2006, 46 ( 10 ) : 1171-1178.
  • 7Lee DG, Choi SM, Shin WS, et al. Population pharmacoki- netics ofmeropenem in febrile neutropenic patients in Korea [J]. Int JAntimicrobAgents, 2006, 28 (4) : 333-339.
  • 8Bafeltowska J, Pokorska A, Bialek K, et al. Application of HPLC to meropenem determination in plasma samples of patients with infections treated after coronary artery by pass graft surgery [J]. Rocz Panstw Zakl Hig, 2010, 61 ( 3 ) : 323-327.
  • 9Robatel C, Buclin T, Eckert P, et al. Determination of meropenem in plasma and filtrate-dialysate from patients under continuous veno-venous haemodiafiltration by SPE-LC [J]. J PharmBiomedAnal, 2002, 29 (1-2) : 17-33.
  • 10Leelarasamee A, Rongrungruang Y, Trakulsomboon S, et al. Bioequivalence, antibacterial activity and therapeutic outcome of a generic meropenem ( Mapenem ) [J]. J Med Assoc Thai, 2008, 91 (7) : 980-988.

共引文献85

同被引文献55

引证文献7

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部